Evidence Intelligence™
- EvidenceScore™
- 82
- Strong
- ImpactScore™
- 64
- Slightly Positive
- ConsistencyScore™
- 57
- generally_consistent
Supporting studies: Based on 7 studies
Add to Evidence TrackerResearch Summary
Analyzed using Evidence Intelligence™
Semaglutide improves cardiovascular outcomes in high-risk patients
Last updated July 8, 2026
Key finding
The primary endpoint occurred less frequently in the semaglutide group than in the placebo group: 331 vs. 410.
The study evaluated semaglutide, a glucagon-like peptide-1 receptor agonist, for managing high cardiovascular risk and found significant reductions in major renal events and cardiovascular risks.
Quick read
Study at a glance
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Short-Term (≤3 mo)
Risk of bias
Some Concerns
Save research, organize studies, and quickly find important evidence again.
Plain-language summary
What this paper says
A plain-language read of the study’s main message and where it applies.
Study focus
The study evaluated semaglutide, a glucagon-like peptide-1 receptor agonist, for managing high cardiovascular risk and found significant reductions in major renal events and cardiovascular risks.
Clinical relevance
These findings are clinically significant as they suggest that semaglutide can be an effective treatment option for patients at high cardiovascular risk, potentially improving both kidney health and overall survival. This could lead to better management strategies for patients with diabetes and cardiovascular conditions.
Keep in mind
The study may have limited generalizability due to specific inclusion criteria. Potential biases in self-reported outcomes could affect results. Long-term effects beyond the study duration are unknown.
Published in
Journal Reference
Publication details and source links for this paper.
Laura G, Flavio GB, Antonio EL, Lorenzo S, Francesco P. Semaglutide: A glucagon-like peptide-1 receptor agonist for managing high cardiovascular risk. European Heart Journal Supplements: Journal of the European Society of Cardiology. 2025;27(Suppl 3):iii98-iii101. doi:10.1093/eurheartjsupp/suaf024
Main Effects
Semaglutide group had 79 fewer major renal events compared to placebo (331 vs. 410 events; P = 0.0003).
eGFR decline was slower in the semaglutide group (−2.19 vs. −3.36 mL/min/1.73 m² per year; P < 0.001).
Risk of major cardiovascular events was 18% lower in the semaglutide group (HR 0.82; P = 0.029).
All-cause mortality was reduced by 20% in the semaglutide group (HR 0.80; P = 0.01).
Evidence network
How this study fits
Understand where this research contributes within the broader evidence network.
Evidence Context
This study contributes evidence to Semaglutide and All-cause mortality, Annual rate of change in eGFR, Cardiovascular events, and 2 more.
This study contributes evidence to
Primary intervention
Semaglutide
Primary outcomes
- All-cause mortality
- Annual rate of change in eGFR
- Cardiovascular events
Evidence topics
Primary intervention
Evidence relationships
Intervention and outcome relationships this study adds to the evidence network.
5
Evidence pairs
5
Relationships
2
Evidence topics
contributes_evidence
Editorial context
Why this study matters
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
Moderate contributionModerate confidenceNetwork score: 68
2
Related topics
5
Evidence pairs
120
Related studies
High relevance in at least one topic
Why it is useful
- Contributes to 5 evidence relationships
- Includes primary outcome data
- Linked to 2 direct semantic evidence topics
Topic contributions
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Add related evidence to your Evidence Tracker
Save studies and evidence pages, organize your personal Evidence Tracker, and keep the research you care about in one place.
Primary evidence
Evidence relationship
GLP-1 Receptor Agonists and Cardiovascular Outcomes
Related evidence
Evidence topic
Cardiovascular Risk
Save evidence
Evidence topic
GLP-1 Receptor Agonists
Save evidence
Core evidence
Study findings
The primary outcomes reported in this study.
Annual rate of change in eGFR
Semaglutide → Annual rate of change in eGFR
Semaglutide → Annual rate of change in eGFR
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- 79
- Strong
- ImpactScore™
- 88
- Very Positive
- ConsistencyScore™
- 75
- consistent
Supporting studies: Based on 4 studies
Add to Evidence TrackerMajor kidney disease events composite including end-stage renal disease, sustained eGFR decline, and death from renal or cardiovascular causes
Semaglutide → Major kidney disease events composite including end-stage renal disease, sustained eGFR decline, and death from renal or cardiovascular causes
Semaglutide → Major kidney disease events composite including end-stage renal disease, sustained eGFR decline, and death from renal or cardiovascular causes
Evidence Intelligence™
- EvidenceScore™
- Moderate
- Score 69 · Based on 2 studies
- ImpactScore™
- 75
- Positive
- ConsistencyScore™
- 35
- mixed
Supporting studies: Based on 2 studies
Add to Evidence TrackerRelative risk reduction for major renal events
Semaglutide → Relative risk reduction for major renal events
Semaglutide → Relative risk reduction for major renal events
Evidence Intelligence™
- EvidenceScore™
- Moderate
- Score 69 · Based on 2 studies
- ImpactScore™
- 75
- Positive
- ConsistencyScore™
- 35
- mixed
Supporting studies: Based on 2 studies
Add to Evidence TrackerEvidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
Evidence Suggest
- Semaglutide reduced major renal events by 24% (HR 0.76; P = 0.0003).
- Slower eGFR decline in semaglutide group by 1.17 mL/min/1.73 m² (P < 0.001).
- 20% lower all-cause mortality risk with semaglutide (P = 0.01).
Who this applies to
- Adults with high cardiovascular risk.
- Patients with diabetes and renal impairment.
Keep in Mind
- Results may not apply to populations outside the study criteria.
- Further research is needed to confirm long-term benefits.
- The study focused on specific endpoints, which may not capture all relevant outcomes.
Between the Lines
- The study may have limited generalizability due to specific inclusion criteria.
- Potential biases in self-reported outcomes could affect results.
- Long-term effects beyond the study duration are unknown.
Evidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
Connected Evidence
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on GLP-1 Receptor Agonists and Cardiovascular Outcomes, GLP-1 Receptor Agonists and Cardiovascular Outcomes.
Related evidence relationships
Explore in Evidence ExplorerThis study contributes to the evidence on the following intervention-outcome relationships.
Medications
Evidence Intelligence™
- EvidenceScore™
- 82
- Strong
- ImpactScore™
- 64
- Slightly Positive
- ConsistencyScore™
- 57
- generally_consistent
Supporting studies: Based on 7 studies
View evidenceMedications
Evidence Intelligence™
- EvidenceScore™
- 79
- Strong
- ImpactScore™
- 88
- Very Positive
- ConsistencyScore™
- 75
- consistent
Supporting studies: Based on 4 studies
View evidenceIncluded in these evidence collections
Curated evidence collections and hubs this study is part of.
Cardiovascular Outcomes Evidence Hub
All studies measuring Cardiovascular Outcomes
7 studies
outcome_hubMeasures Cardiovascular Outcomes as a key outcome.
GLP-1 Receptor Agonists Evidence Hub
All studies on GLP-1 Receptor Agonists
7 studies
intervention_hubContributes to GLP-1 Receptor Agonists evidence base.
Recent Diabetes Research
Latest published studies
recency_collection
Published within the last 2 years.
Explore more in Evidence Explorer
Jump to pre-filtered views in Evidence Explorer.
All studies on Semaglutide and All-cause mortality
Intervention: SemaglutideOutcome: All-cause mortality
7 results
All studies on Semaglutide and Cardiovascular events
Intervention: SemaglutideOutcome: Cardiovascular events
4 results
All studies on Semaglutide
Intervention: Semaglutide
7 results
All studies measuring All-cause mortality
Outcome: All-cause mortality
7 results
All studies measuring Cardiovascular events
Outcome: Cardiovascular events
4 results
Questions answered by this study
Generated from the study's connected evidence using Evidence Intelligence™.
Do GLP-1 Receptor Agonists improve cardiovascular outcomes?
Strong Evidence
GLP-1 Receptor Agonists may improve cardiovascular outcomes.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
All-cause mortality
EvidenceScore™ Strong | EvidenceScore™ 82.3 | weak positive | ConsistencyScore™ Generally Consistent | 1 study
- 2
Cardiovascular events
EvidenceScore™ Strong | EvidenceScore™ 78.7 | strong positive | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on 13 supporting studies with consistent results and a positive effect signal.
Does Semaglutide improve major kidney disease events composite including end-stage renal disease, sustained egfr decline, and death from renal or cardiovascular causes?
Moderate Evidence
Semaglutide may improve major kidney disease events composite including end-stage renal disease, sustained egfr decline, and death from renal or cardiovascular causes.
ConsistencyScore™: Results are mixed and should be interpreted cautiously.
Evidence caveat: The available evidence reports mixed findings.
Ranked evidence signals
- 1
Major kidney disease events composite including end-stage renal disease, sustained eGFR decline, and death from renal or cardiovascular causes
EvidenceScore™ Moderate | EvidenceScore™ 69.0 | moderate positive | ConsistencyScore™ Mixed | 1 study
Why this answer: This answer is cautious because the available studies report mixed findings.
Limitations
- Only one supporting study is available.
What evidence is available on Semaglutide and relative risk reduction for major renal events?
Moderate Evidence
Semaglutide may reduce relative risk reduction for major renal events.
ConsistencyScore™: Results are mixed and should be interpreted cautiously.
Evidence caveat: The available evidence reports mixed findings.
Ranked evidence signals
- 1
Relative risk reduction for major renal events
EvidenceScore™ Moderate | EvidenceScore™ 69.0 | moderate positive | ConsistencyScore™ Mixed | 1 study
Why this answer: This answer is cautious because the available studies report mixed findings.
Limitations
- Only one supporting study is available.
Does Semaglutide improve annual rate of change in egfr?
Emerging Evidence
Semaglutide appears to improve annual rate of change in egfr.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Annual rate of change in eGFR
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
Next steps
Continue your research
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Evidence topics
Follow the topics this study contributes to.
Explore in Evidence Explorer
Open broader Evidence Explorer views for this relationship.
All studies on Semaglutide and Major kidney disease events composite including end-stage renal disease, sustained eGFR decline, and death from renal or cardiovascular causesAll studies on Semaglutide and All-cause mortalityAll studies on Semaglutide and Cardiovascular eventsAll studies on Semaglutide and Relative risk reduction for major renal events
Related research
Read related research summaries.
Semaglutide may reduce cardiovascular events in non-diabetic patients.Oral semaglutide reduces cardiovascular events in type 2 diabetesSemaglutide improves insulin sensitivity in adolescents with obesityHigher semaglutide doses improve glucose control in type 2 diabetesNovel Semaglutide Injection Shows Non-Inferior Glycemic Control
No ads. No tracking.
Focused on evidence, not advertising.
Secure & private
Your data is always protected.
Always up to date
New studies added every day.